— Infection Control & Hospital Epidemiology To the Editor Tuberculosis (TB) is one of the top 10 causes of
death worldwide.1 Despite efforts over the last two decades, control of the infection at a global level is still out of reach; however, decreasing trends in Mycobacterium tuberculosis incidence, out- break, and mortality have been observed.2 The best estimate for 2017 is 1.3 million TB deaths (range, 1.2–1.4 million) with an addi- tional 300,000 deaths (range, 266,000–335,000) resulting from TB disease among HIV-positive people.3 Most cases are estimated to have occurred in Asia and Africa, with the highest incidence in China (1,410 million) and India (1,339 million) in 2017.3 According to the data,3,4 Iran has a low TB mortality rate (1 case per 100,000 population, excluding cases of HIV plus TB), com- pared to most neighboring countries such as Afghanistan (29 per 100,000 population), Armenia (1.2 per 100,000 popula- tion), Azerbaijan (8.7 per 100,000 population), Iraq (2.9 per 100,000 population), Turkmenistan (9.9 per 100,000 population), and Pakistan (27 per 100,000 population). Moreover, according to a report by the Ministry of Health and Medical Education of Iran, from 1964 to 2016, the incidence of pulmonary TB with pos- itive sputum smear in Iran decreased by >10 times to 5.7 per 100,000 population in 2016.5 But how has Iran succeeded in con- trolling TB in a region with high burden of tuberculosis and multi- drug-resistant (MDR) tuberculosis? Because Iran is located in a special geographical location,
achieving this result requires huge financial cost, equipment, and time investment for Iran. The country is surrounded by 2 countries with a high burdens of TB (ie, Pakistan and Afghanistan) in the east as well as Iraq in the west (with which Iran is involved in external and internal wars). In addition, Azerbaijan to the north has a high prevalence of MDR-TB. Thus, the challenge to control this disease is substantial, and its success is admirable. There are several important reasons for Iran’s success. (1) Continuation of free treatment and diagnosis for TB patients plays a significant role in TB control. (2) Nine regional TB laboratories in big cities including Tabriz, Shiraz, Isfahan, Mashhad, Kermanshah, Zahedan, Gorgan, Ahvaz, and Tehran distribute alerts about all TB incidents. (3) Improved phe- notypic and genotypic diagnosis, treatment, and follow-up have accompanied the increased quantity and quality of health care
499
in Iran over 50 years, despite economic sanctions. (4) The addition of 3 multidrug-resistant TB treatment centers in Shiraz, Mashhad, and Tabriz cities in southern, eastern and western Iran, respectively, now cover all regions of Iran. (5) Cooperation with the international community has improved, especially with the World Health Organization. (6) The activities of university centers in TB control have improved through skilled personnel training and improving education for the poor regions and sub- urbs. (7) Quality control programs for TB microbiology laborato- ries have been implemented. (8) The number of private medical diagnostic labs in the cities and the villages has grown substantially. (9) Finally, the Ministry of Health and Medical Education on TB program includes follow-up and continuous monitoring. According to the policy objective of the Ministry of Health in Iran, by the year 2025, the detection rate of pulmonaryTB will have increased to >85% and the rate of treatment will have increased to 90%.
Acknowledgments. Financial support. No financial support was provided relevant to this article.
Conflicts of interest. All authors report no conflicts of interest relevant to this article.
References
1. Lohrasbi V, Talebi M, Bialvaei AZ, et al. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Tuberculosis 2018;109:17–27.
2. Punjabi CD, Perloff SR, Zuckerman JM. Preventing transmission of Mycobacterium tuberculosis in health care settings. Infect Dis Clin 2016;30:1013–1022.
3. World Health Organization. Global Tuberculosis Report 2018. Geneva, Switzerland: WHO; 2018.
4. Nasiri MJ, Dabiri H, Darban-Sarokhalil D, Rezadehbashi M, Zamani S. Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis. Am J Infect Control 2014;42:1212–1218.
5. Department of Tuberculosis and Leprosy Control. Iran Ministry of Health and Medical Education website.
http://tb-lep.behdasht.gov.ir/. Accessed February 5, 2019.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122
